Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by peripheral stem cell transplantation in treating children who have newly diagnosed neuroblastoma.
Gender:
ALL
Ages:
30 years and below
Trial Updated:
02/12/2014
Locations: Baylor College of Medicine, Houston, Texas +1 locations
Conditions: Neuroblastoma
Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
Completed
RATIONALE: Drugs used in chemotherapy, such as vinblastine and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vinblastine when given together with carboplatin in treating young patients with newly diagnosed or recurrent low-grade glioma.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
02/11/2014
Locations: Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas +1 locations
Conditions: Brain and Central Nervous System Tumors, Neurofibromatosis Type 1
Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors
Unknown
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. A bone marrow or peripheral stem cell transplant using stem cells from the patient may be able to replace blood-forming cells that were destroyed by chemotherapy. This may allow more chemotherapy to be given so that more tumor cells are killed. PURPOSE: This phase III trial is studying how well giving combination chemotherapy with or with... Read More
Gender:
ALL
Ages:
10 years and below
Trial Updated:
12/17/2013
Locations: M. D. Anderson Cancer Center at University of Texas, Houston, Texas
Conditions: Brain and Central Nervous System Tumors
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
Terminated
Determine whether the addition of CP- 751,871 in combination with paclitaxel plus carboplatin prolongs survival in patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV or recurrent) NSCLC of non adenocarcinoma histology.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2013
Locations: Pfizer Investigational Site, Austin, Texas +17 locations
Conditions: Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
Completed
To determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2013
Locations: Not set, Houston, Texas
Conditions: Carcinoma, Non-Small-Cell Lung, Lung Cancer
ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors
Completed
The purpose of this study is to determine the safety, pharmacokinetics and maximum tolerated dose of ABT-348 as monotherapy and when given in combination with carboplatin or docetaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2013
Locations: Site Reference ID/Investigator# 26524, Houston, Texas
Conditions: Advanced Solid Tumors
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
Completed
Phase 1b Dose Excalation/Expansion: Identify and characterize safety and tolerability of recommended phase 2 dose of CP-751,871 when administered with paclitaxel and carboplatin Phase 1b Erlotinib Extension: To characterize the safety and tolerability of CP751,871 when administered with paclitaxel, carboplatin and erlotinib. Phase 2: To test the efficacy of CP-751,871 combined with paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2013
Locations: Pfizer Investigational Site, Houston, Texas
Conditions: Carcinoma, Non-Small-Cell Lung
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
Completed
The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung cancer receiving gemcitabine and platinum.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2013
Locations: Research Site, Austin, Texas +4 locations
Conditions: Lung Cancer, Chemotherapy-Induced Thrombocytopenia, Non-Small Cell Lung Cancer, Cancer, Lung Neoplasms, Oncology, Solid Tumors, Thrombocytopenia
A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer
Completed
The goal of this study was to determine the effect on overall survival and progression free survival by adding iniparib (BSI-201/SAR240550) to the combination of gemcitabine/carboplatin in adult patients with triple negative breast cancer (estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor receptor 2 (HER2)-negative). Based on data generated by BiPar/Sanofi, it is concluded that iniparib does not possess characteristics typical of the poly (A... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/13/2013
Locations: Research Site, Austin, Texas +6 locations
Conditions: Breast Cancer
Combination Chemotherapy in Treating Children With Progressive Brain Tumors
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens and comparing how well they work in treating children with low-grade astrocytomas or other residual tumors of the brain.
Gender:
ALL
Ages:
9 years and below
Trial Updated:
09/06/2013
Locations: Texas Tech University Health Sciences Center School of Medicine - Amarillo, Amarillo, Texas +10 locations
Conditions: Brain Tumors, Central Nervous System Tumors
Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin and vincristine, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining carboplatin and vincristine with radiation therapy followed by adjuvant chemotherapy may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy plus radiation therapy followed adjuvant chemotherapy in tre... Read More
Gender:
ALL
Ages:
Between 3 years and 21 years
Trial Updated:
08/22/2013
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Brain Tumors, Central Nervous System Tumors, Neuroblastoma
Lobradimil and Carboplatin in Treating Children With Brain Tumors
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Lobradimil may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of carboplatin and lobradimil in treating children with brain tumors that have not responded to previous treatment.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
08/14/2013
Locations: Texas Tech University Health Sciences Center School of Medicine, Amarillo, Texas +12 locations
Conditions: Brain and Central Nervous System Tumors